Article

Standard expected years of life lost due to malignant neoplasms in Poland, 2000-2014

Małgorzata Pikala1*, Monika Burzyńska2, Irena Maniecka-Bryla3

1 Department of Epidemiology and Biostatistics, the Chair of Social and Preventive Medicine of the Medical University of Łódź, Łódź, Poland, Żeligowskiego 7/9, malgorzata.pikala@umed.lodz.pl
2 Department of Epidemiology and Biostatistics, the Chair of Social and Preventive Medicine of the Medical University of Łódź, Łódź, Poland, Żeligowskiego 7/9, monika.burzynska@umed.lodz.pl
3 Department of Epidemiology and Biostatistics, the Chair of Social and Preventive Medicine of the Medical University of Łódź, Łódź, Poland, Żeligowskiego 7/9, irena.maniecka-bryla@umed.lodz.pl

Address for correspondence:
Małgorzata Pikala, PhD, Medical University of Łódź, Medical University of Łódź, ul. Żeligowskiego 7/9, 90-742 Łódź, Polska
e-mail: malgorzata.pikala@umed.lodz.pl
tel. + 48 42 272 52 33
fax + 48 42 639 32 69

Abstract

The aim of the study was an analysis of mortality trends due to malignant neoplasms in Poland.

The study material was a database, consisting of 1,367,364 death certificates of inhabitants of Poland who died in the period 2000-2014 due to malignant cancer.

In order to calculate years of life lost, the SEYLLp index (Standard Expected Years of Life Lost per living person) was applied. We also calculated AAPC (Average Annual Percentage Change). The SEYLLp index (per 10,000 population) due to malignant neoplasms in Poland in males decreased from 586.3 in 2000 to 575.5 in 2014, whereas in females it increased from 398.6 in 2000 to 418.3 in 2014. The greatest number of lost years of life in 2014 was attributed to lung cancer (174.7 per 10,000 males and 77.3 per 10,000 females), breast cancer in females (64.5) and colorectal cancer in males (39.0). The most negative trends were observed for lung cancer in females (AAPC=3.5%) and for colorectal cancer (AAPC=1.8%) and prostate cancer (AAPC=1.6%) in males. Many lost years could have been prevented by including a greater number of Polish inhabitants in screening examinations, mostly targeted at malignant neoplasm, whose incidence is closely connected with modifiable risk factors.

Keywords: standard expected years of life lost; premature mortality; malignant tumours; trends; Poland
Introduction

The early 1970s in Western Europe marked the beginning of the so-called „cardiovascular revolution”, which was a sequence of changes regarding health [1]. In Poland, similar changes started to be observed only after 1990 [2]. The process of increasing incidence of cardiovascular diseases, which had started at the beginning of the 1960s, was then stopped and mortality due to the above cause between 1991 and 2010 in Poland decreased from 499 to 271 per 100,000 population [3]. Those changes were one of causes of lifespan extension. In 1991 – 2010, the lifespan increased by 6.2 years in males and by 5.5 years in females. A consequence of the health progress, observed in the last two decades, was a change in the epidemiological model of morbidity and mortality in Poland [4, 5]. Currently, similarly to western European countries, malignant neoplasms are becoming the most prominent reason for premature mortality, particularly in people below the age of 65 [6, 7]. Female mortality due to cancers is twice as high as that caused by cardiovascular diseases. World Health Organization (WHO) experts believe that one third of cancers could be avoided, one third could be successfully treated, and in one third of cases the quality of life of cancer patients could be improved [8-10].

More than 100 various oncological diseases are called malignant neoplasms. In males, lung, colorectal and prostate cancer constitute almost 50% of cancer-related mortality. With regards to females, breast, lung, stomach, cervical and ovarian cancer is responsible for 60% of deaths [11]. Lung cancer in males as well as lung and breast cancer in females greatly shape trends in cancer diseases in the Polish population [12]. Prognosticating a cancer risk is highly important for prophylactic and therapeutic purposes. An analysis of historical trends and prognosis, even short-term, allows to evaluate the change in risk factors and the effectiveness of an intervention. This method also enables to evaluate the effectiveness of screening studies. A comparison of the short-term cancer-related mortality prognosis with real rate values can be an invaluable asset in evaluation of screening programmes [13].

Currently, cancer is the second most common cause of death in Poland and Europe, responsible for 27.6% of deaths in Poland, 26.5% of deaths in European Union countries and almost 20% of deaths in the WHO European Region [14]. Over 10 years, the number of cancer-related deaths has increased by 6.3% and in 2011 it contributed to death of 1,281,000 inhabitants of 28 EU countries. 37.1% of deaths in the population below 65 years of age were attributed to cancer. The highest percentage was noted in Holland – 48.0%, whereas the lowest, i.e. 28.4% – in Finland. Since the mid-1980s, the incidence of neoplasm has increased by 32% and mortality due to the above cause decreased by 10% [15, 16].

The number of lost years of life in Poland due to premature mortality or disability, caused by neoplastic diseases, is one of the highest in Europe [17]. The standardized DALY measure for neoplastic diseases in Poland in 2013 was 1,822 per 100,000 whereas it was the highest in Hungary (2,167). In France it was 1,623, in Germany – 1,350, in Greece – 1,255, and the lowest in Cyprus – 794. A direct result of premature mortality is the number of years of life, lost by the Polish population. In order to evaluate health of a particular population, authors of foreign studies on epidemiology are more and more frequently using measures which express premature mortality in units of time lost. Many of them claim that the number of years of lost life is a more reliable measure of mortality than other, commonly used mortality rates, since it more effectively points out social and economic outcome of this phenomenon [18-20]. Measures of years of life lost enable to evaluate progress in treating diseases, because they include information on a decrease in the number of deaths and extended survivability.

There are different approaches to methods of calculation of these measures, depending on the adopted life span limit. According to the PYLL (Potential Years of Life Lost) index, the life span limit ranges from the age of 60 to 80. The life span limit is often controversial, which is definitely a disadvantage of the index. Another disadvantage is ignoring benefits, arising out of health interventions targeted at the oldest social groups. Thus, the PYLL index, being less reliable, is not considered in analyses. A better measure is the so called PEYLL (Period Expected Years of Life Lost) index, according to which a local period of expected life span in each age is considered the life span
The PEYLL index cannot be used to make comparisons over the time or to distinguish between societies, characterized with different expected life span, which is a negative aspect of the index. The SEYLL (Standard Expected Years of Life Lost) index does not have such a negative feature, where, expected life span is adopted in order to calculate the number of years of life lost on the basis of an ideal standard.

The aim of the study was to evaluate mortality trends due to malignant neoplasm in the fifteen-year period, 2000-2014, with the application of standard expected years of life lost.

**Materials and Methods**

The research project was granted an approval of the Bioethics Committee of the Medical University of Lodz on 22 May 2012 No. RNN/422/12/KB.

The study material was a database including 5,601,568 death certificates of all inhabitants of Poland who died in the period 2000 – 2014. Of this number, 1,367,364 people died of malignant cancer. The data were provided by the Department of Information of the Polish Central Statistical Office. The procedure of coding causes of death in Poland is performed in a similar to the one carried out in the majority of countries in the world, by basing on the so called primary cause of death, or the disease which triggered a pathological process, leading to death.

The authors calculated standardized death rates (SDR). The standardization procedure was performed with the use of direct method, in compliance with the European Standard Population, updated in 2012 [21].

Years of life lost were counted and analysed by the method described by Christopher Murray and Alan Lopez in Global Burden of Disease (GBD) [22]. The SEYLL index (Standard Expected Years of Life Lost) is used to calculate the number of years of life lost by the studied population in comparison to the years lost by the referential (standard) population.

There are some methods of calculating lost years of life and the main difference between them is a point of reference, i.e. the level of mortality which is considered “ideal”. In the Global Burden of Disease (GBD) study 2010, WHO experts recommend using life tables, based on the lowest noted death rate for each age group, in countries with population above 5 million [23].

In this study, the SEYLL index was calculated according to the following formula:

\[
SEYLL = \sum_{x=0}^{l} d_x e_x^* 
\]

where:

- \(e_x^*\) – life expectancy, based on GBD 2010 life tables
- \(d_x\) – number of deaths at age \(x\)
- \(x\) – age at which the person died
- \(l\) – last age which the population reaches

The authors also calculated \(SEYLL_p\) (per living person) and \(SEYLL_d\) (per death) indices, where the SEYLL absolute number corresponded to the number of inhabitants and the number of people who died due to the analysed cause [24].
Death causes are coded according to the *International Statistical Classification of Diseases and Health Related Problems – Tenth Revision – ICD-10*. The study analysis included malignant tumours (C00-C97), such as: bladder cancer (C67), brain cancer (C70-C72), breast cancer (C50), cervical cancer (C53), colorectal cancer (C18-C21), leukaemia (C95), liver cancer (C22), lung cancer (C33-C34), ovarian cancer (C56), pancreatic cancer (C25), prostate cancer (C61), stomach cancer (C16).

The analysis of time trends has been carried out with *joinpoint* models and *Joinpoint Regression* program, a statistical software package developed by the U.S. National Cancer Institute for the Surveillance, Epidemiology and End Results Program [25]. This method is an advanced version of linear regression, where time trend is expressed with a broken line, which is a sequence of segments joined in joinpoints. In these points, the change of the value is statistically significant (p<0.05). We have also calculated *annual percentage change* (APC) for each segment of broken lines and *average annual percentage change* (AAPC) for a full range of analysed years with corresponding 95% *confidence intervals* (CI).

**Results**

Standardized death rates (SDR) due to malignant tumours in the period 2000 – 2014 in Poland decreased. In 2000 SDR was 47.24 per 10,000 males and 24.11 per 10,000 females. In 2014, SDR was 40.51 and 21.90 per 10,000 population respectively (Table 1). In 2014, the highest SDR values, observed in the male group, regarded: lung cancer (11.72), colorectal cancer (5.20) and prostate cancer (4.11); as for the female group, they were the highest for: lung cancer (3.73), breast cancer (3.05) and colorectal cancer (2.56). With regards to two cancers, characterized with the highest mortality i.e. colorectal cancer in males and lung cancer in females, SDR in 2014 was higher than SDR in 2000.

The number of standard expected years of life lost per 10,000 males (SEYLL\textsubscript{p}) due to malignant tumours in 2000, was 586.3 (Table 2). In 2000 – 2006, SEYLL\textsubscript{p} values were growing and the annual percentage change (APC) was 0.4% in this period (Figure 1). In 2006, the index value started decreasing at a pace of -0.8% (p<0.05), and in 2014 it was 575.5 per 10,000 males. In 2000 – 2014, the average annual percentage change (AAPC) was -0.3%.

**Figure 1.** Time trends in SEYLL\textsubscript{p} (per 10,000 inhabitants) due to malignant neoplasms in Poland, 2000-2014.
Table 1. Standardized death rates (per 10,000 inhabitants) due to malignant neoplasms in Poland, 2000-2014.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Men</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malignant neoplasms overall</td>
<td>47.24</td>
<td>47.96</td>
<td>48.43</td>
<td>47.40</td>
<td>47.76</td>
<td>46.82</td>
<td>46.34</td>
<td>45.48</td>
<td>44.75</td>
<td>43.29</td>
<td>42.30</td>
<td>42.32</td>
<td>41.07</td>
<td>40.51</td>
<td></td>
</tr>
<tr>
<td>Bladder cancer</td>
<td>2.28</td>
<td>2.21</td>
<td>2.31</td>
<td>2.48</td>
<td>2.42</td>
<td>2.25</td>
<td>2.26</td>
<td>2.39</td>
<td>2.33</td>
<td>2.41</td>
<td>2.33</td>
<td>2.37</td>
<td>2.30</td>
<td>2.38</td>
<td>2.25</td>
</tr>
<tr>
<td>Brain cancer</td>
<td>0.97</td>
<td>0.99</td>
<td>0.78</td>
<td>0.83</td>
<td>0.92</td>
<td>1.09</td>
<td>1.07</td>
<td>1.11</td>
<td>1.14</td>
<td>1.06</td>
<td>1.04</td>
<td>1.12</td>
<td>1.05</td>
<td>1.03</td>
<td></td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>4.68</td>
<td>4.82</td>
<td>4.93</td>
<td>4.88</td>
<td>4.92</td>
<td>4.89</td>
<td>5.01</td>
<td>5.20</td>
<td>5.26</td>
<td>5.20</td>
<td>5.27</td>
<td>5.16</td>
<td>5.23</td>
<td>5.14</td>
<td>5.20</td>
</tr>
<tr>
<td>Leukaemia</td>
<td>1.13</td>
<td>1.23</td>
<td>0.99</td>
<td>1.03</td>
<td>1.06</td>
<td>1.31</td>
<td>1.31</td>
<td>1.32</td>
<td>1.29</td>
<td>1.24</td>
<td>1.21</td>
<td>1.31</td>
<td>1.24</td>
<td>1.26</td>
<td>1.23</td>
</tr>
<tr>
<td>Liver cancer</td>
<td>1.01</td>
<td>1.05</td>
<td>0.98</td>
<td>0.99</td>
<td>0.96</td>
<td>0.85</td>
<td>0.94</td>
<td>0.86</td>
<td>0.86</td>
<td>0.87</td>
<td>0.88</td>
<td>0.83</td>
<td>0.91</td>
<td>0.86</td>
<td>0.82</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>1.78</td>
<td>1.76</td>
<td>1.80</td>
<td>1.82</td>
<td>1.79</td>
<td>1.79</td>
<td>1.80</td>
<td>1.84</td>
<td>1.87</td>
<td>1.90</td>
<td>1.82</td>
<td>1.73</td>
<td>1.82</td>
<td>1.77</td>
<td>1.83</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>4.16</td>
<td>4.46</td>
<td>4.57</td>
<td>4.32</td>
<td>4.46</td>
<td>4.36</td>
<td>4.38</td>
<td>4.50</td>
<td>4.31</td>
<td>4.34</td>
<td>4.08</td>
<td>4.17</td>
<td>4.20</td>
<td>4.15</td>
<td>4.11</td>
</tr>
<tr>
<td>Stomach cancer</td>
<td>3.95</td>
<td>3.77</td>
<td>3.78</td>
<td>3.60</td>
<td>3.53</td>
<td>3.34</td>
<td>3.23</td>
<td>3.23</td>
<td>3.11</td>
<td>2.98</td>
<td>2.95</td>
<td>2.86</td>
<td>2.78</td>
<td>2.66</td>
<td>2.63</td>
</tr>
<tr>
<td><strong>Woman</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malignant neoplasms overall</td>
<td>24.11</td>
<td>24.12</td>
<td>23.94</td>
<td>24.06</td>
<td>23.72</td>
<td>23.82</td>
<td>23.68</td>
<td>23.65</td>
<td>23.36</td>
<td>22.98</td>
<td>22.49</td>
<td>22.08</td>
<td>22.45</td>
<td>21.98</td>
<td>21.90</td>
</tr>
</tbody>
</table>

Int. J. Environ. Res. Public Health 2019, 16, x FOR PEER REVIEW
<table>
<thead>
<tr>
<th>Causes of death</th>
<th>SEYLL&lt;sub&gt;p&lt;/sub&gt; (per 10,000)</th>
<th>AAPC</th>
<th>95% CI</th>
<th>SEYLL&lt;sub&gt;d&lt;/sub&gt;</th>
<th>AAPC</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain cancer</td>
<td>0.71</td>
<td>0.65</td>
<td>0.59</td>
<td>0.62</td>
<td>0.66</td>
<td>0.61</td>
</tr>
<tr>
<td>Bladder cancer</td>
<td>0.35</td>
<td>0.37</td>
<td>0.35</td>
<td>0.35</td>
<td>0.35</td>
<td>0.35</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>3.05</td>
<td>3.05</td>
<td>3.01</td>
<td>3.03</td>
<td>2.94</td>
<td>3.06</td>
</tr>
<tr>
<td>Cervix uteri cancer</td>
<td>1.20</td>
<td>1.08</td>
<td>1.09</td>
<td>1.06</td>
<td>1.03</td>
<td>1.00</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>2.87</td>
<td>2.92</td>
<td>2.87</td>
<td>2.87</td>
<td>2.80</td>
<td>2.81</td>
</tr>
<tr>
<td>Leukaemia</td>
<td>0.67</td>
<td>0.70</td>
<td>0.60</td>
<td>0.62</td>
<td>0.62</td>
<td>0.73</td>
</tr>
<tr>
<td>Liver cancer</td>
<td>0.74</td>
<td>0.73</td>
<td>0.68</td>
<td>0.64</td>
<td>0.61</td>
<td>0.57</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>2.56</td>
<td>2.72</td>
<td>2.40</td>
<td>2.48</td>
<td>2.44</td>
<td>2.93</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>1.27</td>
<td>1.32</td>
<td>1.31</td>
<td>1.36</td>
<td>1.33</td>
<td>1.37</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>1.26</td>
<td>1.23</td>
<td>1.23</td>
<td>1.29</td>
<td>1.20</td>
<td>1.21</td>
</tr>
<tr>
<td>Stomach cancer</td>
<td>1.48</td>
<td>1.47</td>
<td>1.37</td>
<td>1.35</td>
<td>1.28</td>
<td>1.20</td>
</tr>
</tbody>
</table>

Table 2. Standard expected years of life lost in males due to malignant neoplasms in Poland, 2000-2014.
<table>
<thead>
<tr>
<th>Disease</th>
<th>SEYLL(_p)</th>
<th>SEYLL(_d)</th>
<th>AAPC</th>
<th>CI</th>
<th>CI</th>
<th>CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bladder cancer</td>
<td>20.3</td>
<td>24.3</td>
<td>1.3*</td>
<td>1.0</td>
<td>1.7</td>
<td>18.8</td>
</tr>
<tr>
<td>Brain cancer</td>
<td>20.7</td>
<td>23.0</td>
<td>0.6*</td>
<td>0.2</td>
<td>1.0</td>
<td>31.4</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>29.5</td>
<td>39.0</td>
<td>1.8*</td>
<td>1.1</td>
<td>2.5</td>
<td>20.2</td>
</tr>
<tr>
<td>Leukaemia</td>
<td>17.8</td>
<td>17.8</td>
<td>-0.3</td>
<td>-0.7</td>
<td>0.0</td>
<td>26.9</td>
</tr>
<tr>
<td>Liver cancer</td>
<td>11.8</td>
<td>12.3</td>
<td>0.2</td>
<td>-0.3</td>
<td>0.7</td>
<td>21.9</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>196.1</td>
<td>174.7</td>
<td>-0.9*</td>
<td>-1.3</td>
<td>-0.6</td>
<td>22.7</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>24.9</td>
<td>28.4</td>
<td>1.2*</td>
<td>0.8</td>
<td>1.6</td>
<td>24.0</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>26.5</td>
<td>34.5</td>
<td>1.6*</td>
<td>1.4</td>
<td>1.9</td>
<td>15.6</td>
</tr>
<tr>
<td>Stomach cancer</td>
<td>45.2</td>
<td>36.3</td>
<td>-1.4*</td>
<td>-1.6</td>
<td>-1.2</td>
<td>21.6</td>
</tr>
</tbody>
</table>

SEYLL\(_p\) - Standard Expected Years of life Lost per living persons

SEYLL\(_d\) - Standard Expected Years of life Lost per deaths

AAPC - Average Annual Percentage Change

CI = Confidence Interval

* \(p<0.05\)
In the female group, the SEYLL\textsubscript{p} index in 2000 was 398.6 per 10,000 females. (Table 3). In the fifteen-year study period, the trend changed twice. In 2000 – 2007, SEYLL\textsubscript{p} values were increasing at an annual pace of 0.7% (p<0.05); in 2007 – 2011, they were decreasing at an annual pace of -0.7%, and from the year 2011, they were growing again, at an annual pace of 0.9%. AAPC for the period 2000 – 2014 was 0.3% (p<0.05). In 2014, the SEYLL\textsubscript{p} index was higher than in 2000, i.e. 418.3 per 10,000 females.

Table 3. Standard expected years of life lost in females due to malignant neoplasms in Poland, 2000-2014.

<table>
<thead>
<tr>
<th>Causes of death</th>
<th>SEYLL\textsubscript{p} (per 10,000)</th>
<th>AAPC</th>
<th>95% CI</th>
<th>SEYLL\textsubscript{d}</th>
<th>AAPC</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malignant neoplasms overall</td>
<td>398.6</td>
<td>418.3</td>
<td>0.3*</td>
<td>0.1</td>
<td>2.0</td>
<td>19.4</td>
</tr>
<tr>
<td>Bladder cancer</td>
<td>4.0</td>
<td>6.0</td>
<td>2.7*</td>
<td>2.2</td>
<td>16.2</td>
<td>15.7</td>
</tr>
<tr>
<td>Brain cancer</td>
<td>17.0</td>
<td>16.8</td>
<td>0.3</td>
<td>-0.4</td>
<td>1.0</td>
<td>28.7</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>57.9</td>
<td>64.5</td>
<td>0.8*</td>
<td>0.2</td>
<td>1.3</td>
<td>24.2</td>
</tr>
<tr>
<td>Cervix uteri cancer</td>
<td>28.3</td>
<td>19.9</td>
<td>-2.1*</td>
<td>-2.5</td>
<td>-1.8</td>
<td>28.0</td>
</tr>
<tr>
<td>Colorectal cancer</td>
<td>24.0</td>
<td>28.0</td>
<td>0.9*</td>
<td>0.5</td>
<td>1.3</td>
<td>17.9</td>
</tr>
<tr>
<td>Leukaemia</td>
<td>12.2</td>
<td>11.3</td>
<td>-1.0*</td>
<td>-1.5</td>
<td>0.4</td>
<td>22.9</td>
</tr>
<tr>
<td>Liver cancer</td>
<td>10.1</td>
<td>7.2</td>
<td>-2.5*</td>
<td>-3.4</td>
<td>-1.6</td>
<td>18.4</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>46.5</td>
<td>77.3</td>
<td>3.5*</td>
<td>3.2</td>
<td>3.8</td>
<td>22.8</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>26.0</td>
<td>30.1</td>
<td>0.7*</td>
<td>0.1</td>
<td>1.4</td>
<td>25.2</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>17.6</td>
<td>22.4</td>
<td>1.6*</td>
<td>1.2</td>
<td>2.0</td>
<td>18.7</td>
</tr>
<tr>
<td>Stomach cancer</td>
<td>20.5</td>
<td>17.0</td>
<td>-1.6*</td>
<td>-2.0</td>
<td>-1.1</td>
<td>18.7</td>
</tr>
</tbody>
</table>

SEYLL\textsubscript{p} - Standard Expected Years of life Lost per living persons
SEYLL\textsubscript{d} - Standard Expected Years of life Lost per deaths
AAPC - Average Annual Percentage Change
CI – Confidence Interval
* p<0.05

An analysis of particular cancers confirmed that lung cancer contributes to the greatest number of years of life lost in males. However, values of this index are steadily decreasing. In 2000, the SEYLL\textsubscript{p} index was 196.1 per 10,000 males. In 2000 – 2007, the annual pace was -0.2%; since 2007, the annual decrease has been more rapid, i.e. 1.7% (p<0.05). This decline trend in males also regarded the SEYLL\textsubscript{p} index due to stomach cancer (APC=-1.4%, p<0.05). With regards to leukaemia and liver cancer, SEYLL\textsubscript{p} values were quite stable (APC=0.3% and 0.2%, respectively). With regards to all remaining malignant tumours, the SEYLL\textsubscript{p} index for the male group, increased in the period 2000 – 2014. High values of the SEYLL\textsubscript{p} index (29.5 in 2000, and 39.0 in 2014) as well as high AAPC values (1.8%, p<0.05) were observed for colorectal cancer. On the other hand, APC dropped from 2.7% in 2000 – 2008 to
0.6% in 2008–2014 (Figure 2). Prostate cancer contributed to a gradual annual 1.6% increase. The SEYLL$_p$ index per 10,000 males due to the above cause increased from 26.5 in 2000 to 34.5 in 2014. A stable increase was also observed for bladder cancer (AAPC=1.3%, p<0.05), pancreatic cancer (AAPC=1.2%, p<0.05) and brain cancer (AAPC=0.6%, p<0.05).

In the female group, the most negative trend was observed for lung cancer. The SEYLL$_p$ index, which in 2000 was 46.5 per 10,000 females, was growing in the fifteen-year study period by 3.5% annually, and in 2014 its value was 77.3 (Table 3). The second disease, which contributes to the highest number of years of life lost in females, is breast cancer. In 2000, the SEYLL$_p$ index was 57.9 per 10,000 females. In the period 2000–2007, it was increasing by 0.6% annually (p<0.05), whereas, in 2007–2010, it was decreasing by -1.2% (p>0.05). In 2010, the value started to increase again and the annual increase rate was 2.6% (p<0.05). An increase trend was also observed for pancreatic cancer (AAPC=1.6%, p<0.05), colorectal cancer (AAPC=0.9%, p<0.05) and ovarian cancer (AAPC=0.7, p<0.05). With regards to the last mentioned cancer group, since 2007, the SEYLL$_p$ index has not been growing (Figure 2). Low SEYLL$_p$ index values, but a rapid increase in the pace of these values, were observed for bladder cancer (AAPC=2.7%, p<0.05). A positive trend, i.e. a decrease in the number of years of life lost was noted for cervical cancer (AAPC=-2.1%, p<0.05), liver cancer (AAPC=-2.5%, p<0.05), stomach cancer (AAPC=-1.6%, p<0.05) and leukaemia (AAPC=-1.0, p<0.05).
Figure 2. Time trends in SEYLLp (per 10,000 inhabitants) due to the most common malignant neoplasms in Poland, 2000-2014.

The authors revealed that the number of years of life lost by 1 person who died of malignant neoplasm (SEYLLd) was decreasing in both males and females. Each male who died due to a disease included in this disease group in 2000 lost on average 22.6 years of life. In 2014, this number was 20.3...
years (AAPP=0.8%, p<0.05). With regards to females, the SEYLLd index decreased from 21.5 in the year 2000 to 19.4 in the year 2014 (AAPP=0.7%, p<0.05). Values of the SEYLLd index indicate that in 2014 the following diseases contributed to the highest number of lost years of life in males: brain cancer (27.7), leukaemia (21.4), pancreatic cancer (21.4), liver cancer (21.2), lung cancer (20.5) and stomach cancer (20.0). Each female who died in Poland in 2014 lost on average more than 20 years of life due to: brain cancer (24.7), cervical cancer (24.3), ovarian cancer (22.4), breast cancer (21.4) and lung cancer (20.9). A significant decrease in the SEYLLd index was observed for almost all of the studied causes of death in both males and females (except for bladder cancer in females).

Discussion

Neoplasms are the main cause of mortality in many developed countries and the second most common cause in developing countries. In various parts of the world people are affected by various kinds of cancer. Studies conducted by the American Cancer Society reveal that the most common kinds of cancer, occurring in developed countries, include prostate cancer, lung and bronchial cancer, colorectal cancer and breast cancer [26].

A study, conducted in 60 countries from 6 continents in the period 2000 – 2010 confirmed a global decrease in neoplasm-related mortality. The average annual decrease was 1.2% for males and 0.8% for females. In most of the countries – 41/60 in males and 35/60 in females – the annual decrease was 1.0% or above. A decrease was observed for the majority of the most common cancers, except for liver cancer, for which mortality indices were growing in half of the studied countries, particularly in Latin America and North America. Besides, in most countries, female mortality related to lung cancer increased [27, 28]. These findings correspond to results obtained in previous studies. Data included in GLOBOCAN 2002 [29] and 2012 [30] indicate that the cancer-related mortality rate was decreasing in the study period at an annual pace of 1.0% in females and 0.8% in males. Consequently, the decreasing death rate resulted in a reduction of deaths by 814,000 in the period 2002 – 2012. In 1991 – 2010, in the United States, the annual average pace of change was -1.06% [31]. A decrease in APC values (APC ≥-1.0%) was also noted in Europe [32] and other countries, including Asian, African and Latin American countries with an average and low income [33,34]. Apart from demographic characteristics, also three other determining factors contribute to the occurrence of different death rates. They include: 1) frequency of risk factors, 2) screening tests and other methods of early diagnostics, 3) access to treatment. Mortality rates, almost exclusively associated with modifiable risk factors, mostly refer to lung, gastric and liver cancers. These mortality trends mostly depend on incidence rates and are less attributed by economic inequalities [35]. Similar male and female smoking patterns are translated into an increase in the lung cancer incidence in females, which entails an increase in the death rate due to this cause in the female subpopulation. Although the frequency of smoking tobacco decreased, the mortality rate due to lung cancer is becoming similar in males and females in some European countries, and we can expect that its value will be increasing in females all around the world [36].

Lung cancer is the most common cancer affecting men (it constitutes 20% of disorders and contributes to 30% of deaths). For almost two decades, the incidence of this disorder has been decreasing. This positive trend results from a decrease in tobacco smoking in males of all ages. A different trend was observed in females in whom active smoking is different due to cohort effect (date of birth in calendar time). The highest smoking level was observed in women born between 1940 and 1960; in certain periods it was as high as 50%. In the population of females born after 1960, the frequency of smoking dropped by half and was 20 – 25%. Currently occurring malignant neoplasms, affecting women of various ages, are closely associated with their exposure to carcinogenic factors during a twenty-year latency period. The observed cohort effect indicates that this kind of cancer and cancer-related mortality are still on the increase and this growing trend will be observed for some time [37]. The authors of the study made the problem more evident when they revealed quite a considerable increase in the number of years of life lost due to lung neoplasms in 2000 – 2014. APC
in this period was 3.5%. In Poland, Tobacco Attributable Fraction is estimated to be around 80 – 90% in males and around 60 – 70% in females [38]. In non-smokers, the incidence of malignant lung neoplasm is very low, i.e. 5 per 100,000 population [39]. Experiments and epidemiological studies conducted in Poland and other countries confirm the effectiveness of eradication of tobacco in combating lung neoplasm. It is worth comparing time trends of mortality due to lung malignancy in young adult males in Poland and Hungary. In the 1960s and 1970s, the trends were almost identical. After initiating an anti-nicotine campaign in Poland in the 1990s, they became different. In Hungary, the incidence of lung malignancy was one of the highest in the world, whereas in Poland, it started to decline. In Hungarian females, mortality rates were almost three-fold higher than in Poland [40].

In some European countries, malignant neoplasms of the lung constitute the most important cause of mortality due to neoplasms in females and they outnumber breast cancer in this respect. In Poland the number of years of life lost due to breast cancer stopped growing in 2007. However, since 2010, a negative increasing trend has been observed again (APC = 2.6%). With regards to other countries, we observe decreasing mortality rates due to breast cancer, particularly in high-income countries of Europe and North America. Breast cancer-related mortality has started decreasing, or at least, stopped increasing in most countries all around the world. This positive trend is associated with advances in cancer treatment and implementation of breast cancer screening tests. However, a relationship between early diagnostics and screening tests and a decrease in breast cancer-related mortality is still disputable [41-43].

Malignant neoplasm of the prostate is the second most common neoplasm in Poland (almost 11,000 diagnosed cases in 2012). The frequency of diagnosing of this disease has been rapidly growing, particularly since the beginning of this century. Better detection, attributed by screening tests, and poor or no access to treatment resulted, at least to some extent, in increased mortality due to prostate neoplasm in Latin America, low-income Asian countries, and also in post-Soviet countries. In Poland, as it was revealed by the authors, the number of standard expected years of life lost due to this cause increased from 26.5 to 34.5 (APC = 1.6%) between 2000 and 2010.

Colorectal cancer is the third most commonly observed cancer in males and the second in females. In 2012, almost 17,000 developed this disease (around 9.5 males and 7.5 females). The incidence of colorectal cancer is growing in both sexes but in males it is twice as high as in females. In 2012, the total number of deaths due to colorectal cancer exceeded 11,200 (above 6,100 in males and 5,100 in females). The time trend of incidence and mortality is highly different for Poland and countries of the European Union. For the first time in the last decade female mortality started to decrease and the mortality rate in males remained stable, which is a positive phenomenon. The authors of the study also noted a decrease in the pace of losing standard expected years of life due to colorectal cancer from 2.7% in 2000 – 2008 to 0.6% in 2008 – 2014. Only implementation of efficient nationwide early diagnostics and a therapy programme will provide effective control of colorectal cancer [44, 45]. The mortality rate, caused by colorectal cancer, particularly in males, is still increasing in Poland.

Cervical cancer occurs relatively rarely. In 2012, around 2,800 females developed the disease and 1,700 females died of it. However, due to the fact that Polish population is more threatened with this disease than any other nations, the disease is carefully monitored and constitutes a measure of public health. Besides, we are familiar with the etiology of the disease and methods of prevention as well as able to detect it in its early stage and eradicate it by carrying out vaccination. The incidence of cervical malignant neoplasms has been decreasing in Poland since the 1980s and in the last decade the decrease was even more rapid. Cervical cancer-related mortality has also been decreasing for long. Yet, the mortality level in Poland is still higher than in any western countries of the European Union. It is however lower than in many neighbouring countries, e.g. Baltic states. A small number of less educated and less wealthy women, often inhabitants of small towns and villages, undergoing screening tests, poses a serious problem [46]. Inclusion of a greater number of such women is a great challenge. A decline in mortality due to cervical malignant neoplasms in women aged 30 – 74 is much more rapid than in Denmark, Finland or Great Britain than in Poland. Hence, the death rate due to this cause, observed at the end of the first decade of the 21st century, is much lower [47]. Cervical
cancer-related mortality in Poland is one of the highest in Europe, but as it was noted by the authors of the study, over the last fifteen years, the number of years of life lost due to the above disease has been decreasing (AAPC=-2.5%).

It is estimated that decreased stomach cancer-related mortality has mostly contributed to a decrease in the death rate due to neoplasms (APC=-2.7% in males and -2.8% in females). The most noticeable decline was observed in Asia, Latin America and post-Soviet countries. Decreased mortality was also observed in the US in 2004 – 2013 (AAPC=-1.1%). The authors of this study confirmed that the number of years of life lost due to stomach cancer decreased in the period 2000 – 2014. APC for males was -1.4%, and for females -2.5%. The decrease in the incidence of stomach cancer, observed for a few decades, is to a great extent associated with monitoring of Helicobacter pylori infections [48, 49]. Fresh alimentary products have become widely available; people undergo screening tests and hygiene in countries much affected by stomach cancer has substantially improved [50].

Conclusions

The analysis of changes in the number of years of life lost due to neoplastic diseases affecting inhabitants of Poland, conducted over 15 years, points out high values of the SEYLL_index and negative trends regarding lung cancer in females, prostate cancer in males and colorectal cancer in both males and females. Since 2010, the number of years of life lost due to breast cancer in females has also been increasing. We could avoid such a great loss by including more inhabitants of Poland in screening tests, aiming at detecting those malignant neoplasms whose incidence is closely associated with modifiable risk factors. Besides, there is a need to implement programmes on health promotion, including smoking cessation, particularly targeted at young women.

Author Contributions

Conceptualization, Małgorzata Pikala, Monika Burzyńska and Irena Maniecka-Bryła; Formal analysis, Małgorzata Pikala; Methodology, Małgorzata Pikala; Supervision, Irena Maniecka-Bryła; Writing – original draft, Małgorzata Pikala and Monika Burzyńska.

Funding: The work was supported by Medical University of Lodz (project no 503/6-029-07/503-61-002-18).

Conflicts of Interest: The authors declare no conflict of interest.

References


